(Q38100271)

28 August 2017

title

Advances in the treatment of inherited coagulation disorders (English)

1 reference

28 August 2017

M A Escobar

1

1 reference

28 August 2017

language of work or name

1 reference

22 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

19

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

648-659

1 reference

Current options and new developments in the treatment of haemophilia

28 August 2017

cites work

1 reference

The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics

21 January 2018

1 reference

Purification and characterization of a new recombinant factor VIII (N8).

21 January 2018

1 reference

Functional characteristics of N8, a new recombinant FVIII.

21 January 2018

1 reference

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.

21 January 2018

1 reference

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

21 January 2018

1 reference

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

21 January 2018

1 reference

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

21 January 2018

1 reference

Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

21 January 2018

1 reference

Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients.

21 January 2018

1 reference

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

21 January 2018

1 reference

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

21 January 2018

1 reference

Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.

21 January 2018

1 reference

Prolonged activity of factor IX as a monomeric Fc fusion protein

21 January 2018

1 reference

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

21 January 2018

1 reference

Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants

21 January 2018

1 reference

Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice

21 January 2018

1 reference

Hemophilia clinical gene therapy: brief review

21 January 2018

1 reference

The gene therapy journey for hemophilia: are we there yet?

21 January 2018

1 reference

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

21 January 2018

1 reference

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors

21 January 2018

1 reference

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

21 January 2018

1 reference

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

21 January 2018

1 reference

Variants of recombinant factor VIIa with increased intrinsic activity.

21 January 2018

1 reference

Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor

21 January 2018

1 reference

Factor VII mutant V154G models a zymogen-like form of factor VIIa.

21 January 2018

1 reference

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).

21 January 2018

1 reference

Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.

21 January 2018

1 reference

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa

21 January 2018

1 reference

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

21 January 2018

1 reference

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

21 January 2018

1 reference

Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management

21 January 2018

1 reference

Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency

21 January 2018

1 reference

Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers.

21 January 2018

1 reference

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.

21 January 2018

1 reference

Biological rationale for new drugs in the bleeding disorders pipeline

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HAE.12137

1 reference

28 August 2017

1 reference